Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 in Advanced Solid Tumours
NCT05154604Phase 1Unknown
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of tizetatug rezetecan in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose Limited Toxicity at 21 Days, Maximum Tolerable Dose at 21 Days and 2 more. Status: unknown.
02
Drugs
tizetatug rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05154604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154604.